Pembrolizumab + Ibrutinib
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colon Cancer
Conditions
Colon Cancer, Colorectal Cancer, Colorectal Carcinoma, Colon Disease
Trial Timeline
Jan 24, 2018 → Sep 9, 2021
NCT ID
NCT03332498About Pembrolizumab + Ibrutinib
Pembrolizumab + Ibrutinib is a phase 1/2 stage product being developed by Merck for Colon Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03332498. Target conditions include Colon Cancer, Colorectal Cancer, Colorectal Carcinoma.
What happened to similar drugs?
4 of 14 similar drugs in Colon Cancer were approved
Approved (4) Terminated (5) Active (6)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03514017 | Phase 2 | Terminated |
| NCT03332498 | Phase 1/2 | Completed |
Competing Products
20 competing products in Colon Cancer